SOURCE: NanoInk, Inc.

March 12, 2007 12:37 ET

NanoInk Licenses Dip Pen Nanolithography Technology From Arrowhead Research

SKOKIE, IL -- (MARKET WIRE) -- March 12, 2007 -- NanoInk, Inc., a Skokie-based company specializing in nanometer-scale manufacturing and applications development for the life science and semiconductor industries, has exclusively licensed intellectual property from Arrowhead Research Corporation (NASDAQ: ARWR). The licensed technology was developed through Arrowhead's sponsored research at the laboratory of Dr. Patrick Collier at the California Institute of Technology.

The licensed patent application covers techniques related to use of surfactants to support NanoInk's Dip Pen Nanolithography® (DPN®) technology. Dip pen nanolithography involves deposition of nanoscale materials onto a substrate for applications in the life sciences and semiconductor industries.

"The dip pen nanolithography project was one of the first to be sponsored by Arrowhead, and we have worked with Dr. Collier and Caltech to patent the inventions generated under the agreement," said R. Bruce Stewart, Chairman of Arrowhead. "We intend to continue to license Arrowhead's new technologies when the economics make sense, in addition to commercializing products through our subsidiaries."

"Our license from Arrowhead Research Corporation, coupled with several recently awarded patents, strengthens NanoInk's intellectual property portfolio," said Dr. Cedric Loiret-Bernal, NanoInk's Chief Executive Officer. "This intellectual property could play an important role as we continue to explore the applications of our DPN technology to drive the development of high value end products."

About NanoInk

NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the life science and semiconductor industries. With DPN®, a patented and proprietary nanofabrication technology that allows for unmatched flexibility and accuracy, and also its high-resolution Nanoencryption™ technology, NanoInk is able to offer its pharmaceutical customers innovative solutions to fight counterfeiting and illegal diversion of blockbuster pharmaceutical products. Other key applications include nanoscale additive repair and nanoscale rapid prototyping. Located in the new Illinois Science + Technology Park, north of Chicago, NanoInk currently has over 100 issued or pending patents and patent applications filed worldwide and has licensing agreements with Northwestern University, Stanford University, and the University of Illinois at Urbana-Champaign and the Georgia Institute of Technology. For more information on products and services offered by NanoInk, Inc., see www.nanoink.net.

About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) is a publicly traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Contact Information

  • Contacts:
    David Gutierrez
    Dresner Corporate Services for NanoInk
    312-780-7204
    Email Contact

    Virginia E. Dadey
    Arrowhead Research Corporation
    212-541-3707
    Email Contact